We will sell our device to patients through physician prescriptions and insurance reimbursements. We will charge a one-time cost of $1600 for the both wearables, along with two monthly subscriptions, one for an app/patient database and another for the replaceable adhesive patches, each at $30/month.

As SUDEP occurs due to a seizure and then an induced cardiorespiratory collapse, our wearables can transform epilepsy care as a powerful tool with life-saving potential by monitoring and alerting for seizures, cardiorespiratory dysfunctions, and impending SUDEP risk, unlike any other available system. Our solution can also enable SUDEP risk stratification by physicians through documented evidence of seizures and the induced cardiorespiratory dysfunctions. Our device can improve the quality of life of patients and their families through more effective nighttime monitoring, which will improve their quality of sleep, provide peace of mind, and reduce their stress and anxiety. Monitoring for seizures and the induced cardiorespiratory dysfunctions can also provide a more complete picture of each individual's unique presentation, enabling more effective and timely treatment aimed at reducing seizure severity & frequency and minimizing epilepsy-associated comorbidities. Cardiac and respiratory monitoring will also enable us to monitor for multiple types of seizures, unlike our competitors. 

Neurava has established partnerships with world-class clinical collaborators: Dr. George Richerson (Univ. of Iowa), Dr. Nobis (Vanderbilt Univ.), Dr. Samden Lhatoo (UT Health), and Dr. Michael Privitera (Univ. of Cincinnati). They are leading experts in epilepsy and SUDEP, provide clinical guidance to the company, and partners for our clinical studies. Also, we have secured a strategic investment from global epilepsy leader, UCB Biopharma, who bring massive epilepsy related business experience to our team. 

We have also partnered with 3M and their manufacturing partners, Marian Inc., to further develop our wearable adhesive and electrode technology. We have also validated our regulatory strategy through a pre-submission with the FDA and work closely with our regulatory consultants - Dr. Carlos Pena, former FDA CDRH director and former Assistant Director of the White House Office of Emerging technologies (2012-2014) and Dr. Allison Komiyama at RQM+, the world's largest regulatory and quality consulting firm focused on medical devices.

To market our wearable system, we will incorporate a strategy consisting of direct sales, strategic partnerships, and eventually independent contributors/in-house sales team. Given that physician recommendations are the best way to enter the market, we will initially target and form partnerships with the EMUs of our clinical advisors, before scaling to all epilepsy centers in the US and our customer acquisition plan will consist of two fronts, one for physicians and another for patients. For physicians, with early feasibility data in hand, we will present at epilepsy and neurology conferences, like American Epilepsy Society and American Academy of Neurology. In the future, we will also use third party medical device distributors and an in-house sales team to market our product to physicians and other key opinion leaders. On the patient front, the epilepsy community is very close-knit with various support groups and so we will partner with major epilepsy support groups, like the Epilepsy Foundation and the Danny Did Foundation, to raise awareness about SUDEP and our device and use an in-house team to advertise to customers looking to purchase our device directly through both print and social media. We will also leverage our strategic corporate partners, like UCB Biopharma, with an established epilepsy market and incorporate our marketing plan within their existing channels and also engage in joint advertising for our wearable system.